FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 340:1443-1444 May 6, 1999 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Frishman, W. H. PubMed Citation

To the Editor: In his review of carvedilol, Frishman (Dec. 10 issue)¹ did not adequately distinguish the effects of the drug in patients with dilated cardiomyopathy from those in patients with ischemic cardiomyopathy. Bristow et al.² have shown that there are differences between these two disorders in ß-adrenergic activation. The Australia–New Zealand Heart Failure Research Collaborative Group^3,4 has assessed the efficacy of carvedilol in patients with ischemic cardiomyopathy. The investigators reported an increase in symptoms of congestive heart failure with carvedilol as compared with placebo. Carvedilol did result in an increase in left ventricular ejection fraction and a decrease in . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Jeng, W., Ramkissoon, A., Parman, T., Wells, P. G. (2006). Prostaglandin H synthase-catalyzed bioactivation of amphetamines to free radical intermediates that cause CNS regional DNA oxidation and nerve terminal degeneration. FASEB J. 20: 638-650 [Abstract] [Full Text]  
• Kuniyoshi, S. M., Jankovic, J. (2003). MDMA and Parkinsonism. NEJM 349: 96-97 [Full Text]